GlaxoSmithKline (GSK) Posts Quarterly Earnings Results

GlaxoSmithKline (NYSE:GSK) posted its quarterly earnings results on Wednesday. The pharmaceutical company reported $0.72 EPS for the quarter, topping the consensus estimate of $0.69 by $0.03, Morningstar.com reports. The firm had revenue of $10.14 billion for the quarter, compared to the consensus estimate of $9.89 billion. GlaxoSmithKline had a net margin of 7.79% and a return on equity of 115.30%.

Shares of GlaxoSmithKline (GSK) traded up $0.50 during trading on Thursday, hitting $36.53. 5,090,117 shares of the stock traded hands, compared to its average volume of 5,205,498. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44. GlaxoSmithKline has a 1 year low of $34.52 and a 1 year high of $44.53. The company has a market capitalization of $91,350.00, a PE ratio of 42.45, a price-to-earnings-growth ratio of 2.31 and a beta of 0.98.

Institutional investors have recently modified their holdings of the company. Wealthcare Advisory Partners LLC grew its holdings in shares of GlaxoSmithKline by 1,982.8% in the third quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock worth $143,000 after purchasing an additional 3,351 shares during the last quarter. Field & Main Bank bought a new position in shares of GlaxoSmithKline in the fourth quarter worth approximately $132,000. First Dallas Securities Inc. bought a new position in shares of GlaxoSmithKline in the fourth quarter worth approximately $142,000. Advisory Services Network LLC grew its holdings in shares of GlaxoSmithKline by 24.2% in the second quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock worth $175,000 after purchasing an additional 788 shares during the last quarter. Finally, Quadrant Capital Group LLC grew its holdings in shares of GlaxoSmithKline by 3.5% in the second quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock worth $162,000 after purchasing an additional 148 shares during the last quarter. Hedge funds and other institutional investors own 9.66% of the company’s stock.

GSK has been the topic of several research reports. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, October 24th. Zacks Investment Research downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. Investec downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Monday, November 6th. TheStreet raised shares of GlaxoSmithKline from a “c+” rating to a “b” rating in a research note on Wednesday, October 25th. Finally, ValuEngine downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $38.57.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline (GSK) Posts Quarterly Earnings Results” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://sportsperspectives.com/2018/02/08/glaxosmithkline-gsk-posts-quarterly-earnings-results.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Earnings History for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply